Good day, and welcome to the Aurora Spine reports second quarter fiscal year 2022 financial results. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. Please note that this event is being recorded. I would now like to turn the conference over to Adam Lowensteiner, Vice President at Lytham Partners. Please go ahead. Thank you, Cole, and good morning, everyone. Thank you all for joining us today to review the financial results for Aurora Spine for its second quarter ended June 30th, 2022. With us on the call representing the company today are Trent Northcutt, President and CEO of Aurora Spine, and Chad Clouse, CFO of Aurora Spine. Before we begin, I would like to remind everyone that statements made during the course of this call may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These statements reflect current expectations concerning future events and results. Words such as expect, intend, believe, may, will, should, could, anticipate, and similar expressions are words that are used to identify forward-looking statements, but their absence does not mean a statement is not forward-looking. These statements are not guarantees of future performance and are subject to risks and uncertainties and other important factors that could cause actual performance or achievements to be materially different from those projected. For full discussion of these risks, uncertainties, and factors, you are encouraged to read Aurora Spine's documents on file with SEDAR, including those set forth in periodic reports filed under the Forward-Looking Statements and Risk Factors section. Aurora Spine does not intend to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. On this call, management may refer to EBITDA, adjusted EBITDA, adjusted net income, and adjusted EPS, which are not measures of financial performance under generally accepted accounting principles or GAAP. Management believes that these non-GAAP figures, in addition to other GAAP measures, provide meaningful supplemental information regarding the company's operational performance. Investors should recognize that these non-GAAP figures might not be comparable to similarly titled measures of other companies. These measures should be considered in addition to and not as a substitute for or superior to any measure of performance prepared in accordance with GAAP. A reconciliation of non-GAAP measures to the most directly comparable GAAP measures in accordance with SEC Regulation G can be found in the company's earnings release. With that, I'd like to now turn the call over to Mr. Trent Northcutt, President and CEO of Aurora Spine. Trent, please proceed. Thank you, Adam. I'd like to welcome everyone to Aurora Spine's second quarter 2022 financial results conference call. Earlier today, we issued a press release detailing our financial results. Hopefully, you've had a chance to review this news release. If not, a copy can be found on our website at aurora-spine.com. That's aurora-spine.com. Under the investor section and other financial websites, you'll find more listings. To lay out the agenda for today's call, let me first summarize a few events of the quarter, including some brief commentary on the numbers. I'll talk a bit about the status of each key initiative and products like ZIP and SiLO, as our own initiatives of spine division, including the new DEXA line. Chad will then give you a recap of the financial results, and we can conduct a Q&A session at the end. Key events in Q2 and market overview and dynamics in new products and clinical studies. The second quarter was one of the many accomplishments. A major highlight of today's call are the financial results for the second quarter, which produced Aurora's highest quarterly revenue on record. These results demonstrate that investments we placed in 2021 are starting to pay off and our growth strategy is working. In addition to higher revenue, we also delivered solid levels of gross profit margin, which has also revealed that we are selling more proprietary products. We also continue to sell DEXA-C on a limited basis in the second quarter, which is still in beta phase as we gear up for full launch phase later this year. I'll expand on DEXA later in my comments. On a micro level, the momentum we built in the past few quarters has continued into a second quarter. As the pandemic issues in healthcare seem to be mostly behind us and patients are coming out to take care of health issues and doctors are welcoming them back. Also many doctors have pivoted during the pandemic to conduct their procedures at surgery centers so they can schedule procedures and get them completed. Aurora products like the ZIP and the SiLO are very compelling to doctors and their patients. For doctors it means treating patients by conducting procedures in a minimally invasive manner. For patients, they undergo a minor procedure and can usually return home in the same day, usually resuming their normal activity and routines. I believe that these reasons are our products are able to gain traction, and we've been able to in addition to our products are alternative ways for doctors to treat patients as little pain medication as possible, especially given the opioid epidemic that has hit the United States in the recent decade. During the quarter, we continued to work diligently and put focus on our proprietary products by educating doctors through our cadaver lab trainings. In the quarter, we continued to train many doctors and surpass more than 200 we've trained from last year. We are slated to conduct more sessions in the fall and on track to double the number of doctors we trained in 2021. The trainings are done in various cities throughout the United States and allows around 20 doctors to learn more about Aurora products, specifically the ZIP and the SiLO at the same training. The ZIP series continues to lead the charge for Aurora, which was 30.6% of the sales in the second quarter or $1.2 million. Our clinical study for this product is returning solid data and getting the product into the hands of many doctors that didn't know it existed. The product is a key value-add product to many pain interventionalists who can now conduct a fusion procedure in a minimally invasive manner and incorporate such a therapy into their practice and patients, which they didn't offer before. The clinical trial for the ZIP continues, and it is growing very well. As mentioned, it has attracted many new doctors to try the device, and many have embraced it now and have incorporated it into their practice. Subsequent to the quarter end, we announced the FDA clearance of a new lumbar stenosis indication for use in our ZIP family of MIS implants. Spinal stenosis, when the spinal canal narrows, which can lead to back and leg pain. Adding lumbar stenosis to the existing FDA clearance indication for degenerative disc disease and spondylolisthesis, trauma or tumor allows physicians to identify and treat new patient population using the ZIP MIS implant device. The receipt of this additional indication for lumbar spinal stenosis, or LSS, for the ZIP MIS Interspinous Fusion System, is another key milestone for Aurora Spine and allows us to expand our spinal product portfolio and acts as a nice tailwind for the product series that which will open up the ZIP for more potential procedures and would be more attractive option for doctors going forward. SiLO, our SI joint device, also was an important contributor to the company's growth in the second quarter. Its revenues represented 23.5% of the total revenues in the quarter or nearly $1 million. As SI joint procedures continues to be adopted by pain doctors across the country, it is still in its infancy and we expect the SiLO franchise in its own right to have very positive future ahead. As SI joint procedures continue to be introduced to the marketplace, we have been busy making sure that our current supply is available, but also working diligently with the FDA obtaining approvals on our next generation SI joint system, the SiLO TFX, which will be a titanium version with additional fixation capabilities. We continue to conduct biomechanical testing on the product, and the results are coming back positive. We're hopeful for an approval in the coming months. Another area we have advanced our IP during the quarter is our DEXA technology platform. We are secured a key patent with the DEXA, and we have hit the ground running with creating our first DEXA product, the DEXA-C, which stands for cervical, which we obtained FDA clearance during the third quarter in 2021. During the second quarter of 2022, we received 510(k) clearance on our DEXA SOLO-L, which stands for lumbar spinal fusion system, a 3D printed standalone anterior lumbar interbody fusion device, ALIF. The DEXA SOLO-L, part of the DEXA technology platform, is a standalone device for anterior lumbar interbody fusion. This is the first of its kind device for lumbar spine in the world. It's also the first color-coded bone mimicking structure implant in the marketplace and will help doctors match the patient to the patient's bone quality and density. Now with two DEXA products with FDA clearance, we are in the midst of building product sets and inventory and expect to detail these products further in the second half of the year. As supply chain is currently ramping up, we are now working towards marketing of this product, including training sessions and partnerships. Before I pass the call over to Chad, it's important to note that during the second quarter, we also continued to make advancements in our product pipeline as we received a patent from the United States Patent Office for a spinal implant for motion preservation fusion. This patent covers the Aurora ZIPFlex, a technology for minimally invasive posterior interlaminar implant for motion preservation that can be adapted in a fusion or a non-fusion device while implanting into a patient via a small modular attachment. This new patent covers interlaminar motion preservation, fusion, and is also one device that could treat lumbar spinal degeneration. Such as spinal stenosis, we are continuing to work on our prototypes of the ZIPFlex, and we expect to advance it during 2023. This patent shows the improvements we have made with our intellectual property and patent portfolio. We have built Aurora, as we build Aurora and we continue to grow, which has also been important to our investors, we are consistently working and thinking about the next generation of proprietary products that makes it easier for the doctors and for the patients. Summary, I'm extremely proud of our team's performance and staying focused on building this company. We are well-positioned to take advantage of growth markets in several of our new proprietary products. We remain focused on penetrating these markets, furthering this year through continued training sessions and clinical trials. Looking to the long term, we are well-positioned for success, and especially we have new products, more clinical studies proving out our technologies, and reaching more doctors to use the Aurora products. We remain highly focused at the opportunities that are in front of us and continue to invest our growth with each of our major platforms. That's ZIP, SiLO, and the DEXA platform. I will now turn the call over to Chad Clouse, Aurora Spine CFO, who will review the second quarter financial results. Chad, please proceed. Thank you, Trent. Before I proceed with my formal remarks, I want to share that during the quarter, we implemented a new ERP system, which was a major improvement for Aurora going forward. It's already been extremely useful in managing the business, and we anticipate it to allow us to report financial results sooner, which is something I know investors have been requesting. The numbers highlighted in detail in the press release let me focus my comments in a few areas and provide added color where I can. Revenue during the second quarter of 2022 was $4.1 million, a 68% increase from $2.4 million in the second quarter of 2021, and a 15% sequential increase from the $3.6 million in the first quarter of 2022. The improvement in revenues was driven by a strong usage of proprietary products, especially the ZIP and SiLO devices, as well as the introduction of DEXA-C, whereby Q2 was the first full quarter of selling that product. Gross profit in the second quarter was $2.1 million, an increase of 113% from $1 million in the second quarter of 2021, and a 12.6% increase from $1.9 million in the first quarter of 2022. Gross margin was 22.6% in the second quarter of 2022, up from 41.4% recorded in the same quarter a year ago and compared to approximately 53.5% of revenue in the first quarter of 2022. Gross margins showed continued progress and improvement on a year-over-year basis as more proprietary products are part of our revenues. We believe over time that margins have the capability of continued expansion beyond these levels, especially as proprietary product sales increase. Margins in the second quarter would have been even better if it weren't for the rise in shipping costs due to higher energy prices and inflationary pressures in the marketplace. Total revenues in the second quarter were $2.4 million, slightly higher on a sequential basis from the first quarter of 2022 and elevated from Q2 a year ago of $1.9 million as the company continues to make key investments to grow the business, which include new salespeople conducting clinical studies, training sessions, and R&D expenses towards new products. Investors should anticipate these expenses to remain at these levels in the coming quarters, but should peak out next quarter as some R&D expenditures should come to an end. We do believe these investments will put the company in the proper position for accelerated growth and profitability. EBITDA, earnings before interest, taxes, depreciation, and stock-based compensation in the second quarter of 2022 was $96,000, an improvement from the first quarter of 2021, which was a loss of $154,000. Compared year-over-year, EBITDA was a loss of $481,000, but included receipt of a PPP loan of $175,000. Net loss in the second quarter was -$0.2 million or $0.00 per basic and diluted share, an improvement from first quarter of 2022, which was -$0.4 million or -$0.01 per basic and diluted share. An improvement from a net loss of $0.7 million or a negative 1 cent compared to second quarter of 2021 results. These improvements come directly from improved sales and gross margin. Turning to the balance sheet, the company ended the second quarter with $0.8 million in cash and cash equivalents, which we believe to be sufficient to fund the company in the coming quarters. Accounts receivable grew sequentially to approximately $4.1 million from $3.7 million in the first quarter, primarily due to very strong sales in June or the last month of the quarter, similar to what we experienced in the first quarter. That said, receivables peaked at the end of the second quarter and since the quarter's end, we have been recently successful in collecting some of these receivables and believe we are on our way to receiving additional funds in the coming weeks. We are constantly monitoring our receivables and working diligently to collect in a timely fashion. We also continue to build inventory, which increased a little over half a million dollars as we conducted additional trainings and start to also prepare kits for sales of new products. While we have deployed a good amount of capital to these resources, we are hopeful some of these expenses will come to an end in the fourth quarter. We believe we have adequate liquidity to grow the company and achieve profitability. That concludes my comments. I will now turn the conversation back to Trent. Thank you, Chad. Before we open the call to questions, I'd like to include that we believe that we have put the company in a solid track for sizable growth. These several catalysts to take the company to the next level. We used the pandemic to make the investment internally and necessary expenditures to make sure the company captures the opportunities that are evolving in the spine and the pain care markets and the first half results of 2022 are demonstrating the success of these decisions. Some of these new initiatives include building inventory and additional kits and making some key new hires to improve our sales and our licensing efforts. We are very pleased with the progress of these investments and are very excited about the remainder of the year and beyond. Given our very unique situation as an innovative medical device company, we remain very confident that our opportunities to create substantial long-term value for shareholders alike. With that said, operator, we are ready for any questions. Thank you. We will now begin the Q&A session. To ask a question, you may press star then one on your touch-tone phone. If you're using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press star then two. Once again, that is star then one to ask a question. At this time, we'll pause momentarily for the first question. Our first question today will come from Tom Fedichin with Microcap Connection. Please go ahead. Good morning, guys. Congratulations on an excellent quarter. You guys, yeah, you're doing what you're saying, and your sales are obviously proving it out, so congratulations. The question I guess I have would be on DEXA-C. What sort of sales did you see in this quarter? I know I think the previous quarter, I believe, was $280,000. Was it equivalent? That's the first question. Second question is on doctors. You expressed a concern that doctors were gonna take more time off this summer. Have you witnessed that? I've got a few more questions, but I'll leave those two for now, and we can pick it up in a second. Thanks, Tom. Appreciate the kind words. In DEXA-C, we continue to roll that product out in its alpha phase. But the good news is that from the alpha phase, we now have received most of the kits that we were trying to build out. These are the individual instrumentation kits that allow the doctor to size which size implant they're going to use. So from alpha, we'll now move to the beta phase here in September, and we'll be able to move it into a beta phase, and then by the time we get to the fourth quarter, we should be able to go into almost a full release for the DEXA-C technology, which we're really thrilled about. We were able to get a lot of the manufacturing caught up in regards to the DEXA-C implants, and a lot of it was waiting for some of the manufacturing. The supply chain had definitely slowed down, and that ties into your second question, which was vacations. Yes, we did indeed see a lot of vacation. We saw some of this spark up during spring break. We saw people kind of taking a little extra time during spring break off, and that's what was one of the indicators for us that people were gonna be taking some extended vacation times this summer. Yeah, we saw a lot of that in right away in July, where we saw people take, you know, not just say a one-week vacation or two-week vacation. Sometimes they were, you know, three weeks or beyond even 20+ days of vacation time. Some different accounts that work with us, and we've heard about that from other companies as well, that they had some doctors that took some extended time off. Would you say that we're behind that now? That's moving forward, it's kind of full steam ahead and in saying that with DEXA-C and DEXA-L, is there any training required? Knowing you're gonna be doing a full rollout, will you be doing many more of these training sessions but on DEXA-related products going forward? It's a good question. DEXA-C requires no training from the doctors. The doctors are very skilled in cervical fusions, and we're really, you know, it's a nice procedure for them to replicate their existing technique. We've done that with our instrumentation. The tooling that we've made, the instrument kits that we've made are intuitive. The doctors are familiar with it. We have another product in our portfolio, which is called the Discovery Cage, which is a cervical cage, and it mimics that exact technique, which is a high volume procedure. These are the kind of procedures that doctors can put in, you know, eight, 10, you know, even up to 20 implants per month, versus, say like a SiLO, where a doctor might only do, you know, three or four procedures a month with a SiLO device. It's a nice comparison between the two type implants. We expect that the doctors will have no learning curve whatsoever to put in DEXA-C implants. Perfect. How many monthly buying purchasing doctors do you have currently, now, versus, say, the previous months? I think it was 60 in Q1 or as high as 60, I should say. How many do you have today? Let me pull that up. Chad, you've got something quicker than I've got it right here. We are running between about 48 of the doctors that we have. But we had added on from 48. I see here we had another 12 pain interventionalists. That was an add-on to that. That puts us a little bit over 60 from 48 adding on. Yeah, it's just a hair over, but it's consistent. The good news is that some of these customers that we see here that are returning customers each month, like they're continuously using the product and not just a new name. Nice. With the training of SiLO or actually there's no training first for the DEXA, I should say, but with the rollout, would it go to all these previous, like these existing monthly purchasing doctors, these kits that you're pre-producing? That's the plan. You'll have as many kits as there are monthly purchasing doctors. Yeah. If you remember in Q1, we talked about how we were planning a roundtable at the end of April. We did that roundtable with We had 10 scheduled doctors. Nine of them were able to make it. It was a blend of ortho and neuro. We had doctors from universities from around the country, you know, standard practice type of orthopedist or neuro spine surgeons. All came in for that end of August or excuse me, end of April meeting. All nine of those. In fact, I should say all 10 because the one who couldn't make it was just on call, so she couldn't make it. All 10 of those doctors are going to use the DEXA-C implants. We've gone from two users that we were part of that alpha phase now to, you know, four users, and then we're gonna move to all 10 of those users and beyond. We will have by the end of September going into October, we will have over 40 instrument kits available for DEXA-C. Wonderful. Okay. Where do you see profitability? What's the breakeven point for profitability, going forward? It's right there. Like I said before, it's right about, you know, between like $1.1 million-$1.2 million, right in that zone, which is where we've been able to get to, you know, month in and month out. We've had spikes where we've been able to get up to as high as $1.5 million, and I think that's just kind of the, you know, the ebb and flow of the business. I expect the second half of this year, and I don't think I answered one of your question, which was do I see it coming back? You know, people, kids are now going back to school, and it seems like all the schools are open now. I think that that's gonna be key to the second half of this year, is that the doctors are have come off vacation. They're now going back to their practices. Many of them had opened up surgery centers or expanded into surgery centers from the hospital. That was part of the question I didn't answer for you. Then the second part of that is, yeah, I think that this moves us into that profitability area because now we're gonna be able to show a new technology, and it won't be in the alpha phase. It'll be into the beta phase, which will go into a full commercial launch here in the fourth quarter. And those sales are higher volume units, like we'll be able to sell more of those units, be able to do more procedures. Our surgical count will go way up, and the kits will be available to us 'cause we have those kits, you know, now being populated here in the office and will be sent out. We do expect to be profitable in the fourth quarter. Wonderful. Wonderful. Yeah. Okay. Let me jump in there real quick. Just so you know, part of that is you know, our R&D is you know, we've been really spending a lot of money in R&D in the last couple of quarters, and we expect some of that to come to an end in Q3. I think that'll really help Q4 in the end of the year. Okay. Yeah, I kinda gathered that actually from when you were giving your presentation, Chad. That's great. Any supply chain issues at the moment? Well, we still dealt with a lot of nothing that's really glaring at the moment, but definitely things are still trying to kind of unstick themselves in the supply chain. It's not. These are vendors that many of the other companies are using, so it's not like one of our vendors is having problems over somebody else. I just think people are getting caught up. I do think people are coming back to work. I think a lot of it has to still do with the holidays, you know, excuse me, the seasonality of the summer vacations and stuff. I believe that many of these vendors are now starting to try to pick up their strides. Our DEXA manufacturer is right on pace, so they're doing great. We're on par with them. The instrumentation was one of the delays that we had. The tray providers, people who make the surgical kits, which actually moved us into another area where we had to be a little bit creative with how do we get surgical kits available. Our engineering team and our head of our manufacturing came up with just a fantastic solution to allowing us to make new Radel instrument kits. It's a material that we've used in other caddies within our surgical kits, and now we've been able to actually machine these new Radel trays into full-sized kits, which has been great for us 'cause they're lower profile and thinner. The pain interventional doctors love it 'cause it fits into their autoclave, and the surgery centers love it 'cause it's smaller and it's lighter to carry. This actually evolved us, and we're now starting to make more of these smaller surgical kits that fit into the smaller surgery centers' autoclaves. We're kind of proud of ourselves on that model. Nice. Can you speak about approval for SiLO TFX? I know we're all anxiously anticipating the approval. Have you heard anything? When would a full rollout of SiLO TFX take place if approval was had? Yes, we've had to do some additional testing, which we are conducting as we speak. This took us to an area where they were missing in their comments. They said, "We need this one more data point from Aurora." We were already queued up for that, just in case they asked on that, and we did that, and we're in that testing cycle right now. We will come off that testing cycle this month. We'll actually finish it before the month even ends, today being the 29th. It's coming right here to the, you know, probably Wednesday or Thursday this week. Then we'll go back with the testing data, which has been nothing but positive for Aurora, and our device versus the predicate that we're using. We will get that resubmitted, and that puts us back on the clock with the FDA with the remaining 30 days with the FDA. So, if in a best-case scenario that they have everything, say, no later than right after the Labor Day holiday, say 6th, 7th of September, they have everything in their hands. They could give us an FDA approval within that first week of October, and then we would be able to do a couple alpha cases before the year was over in, let's say, towards December. That would give us a lot of time to ramp up and start the manufacturing. We're ready for that, to manufacture the devices. We have key users that will be using the implant, you know, once we get an FDA approval. Fingers are crossed, of course. Okay. Okay. Are there any new device products that we can look forward to seeing in the latter half or hearing about that maybe haven't been discussed? Obviously, when I say hearing about and seeing, I'm not talking released, but just in development. Yeah. We're mostly focused on just the manufacturing and the rollout of all the technologies that we built over the last two years that we've been working on. It's to get the DEXA-C implants out in a full-fledged, you know, a full marketing launch. We do expect to do our first DEXA-L procedure before the year is over, which would be the replacement of our SOLO-L 3D printed ALIF standalone system to be turned to a DEXA implant. We do expect to at least have that device available to a couple of alpha users, you know, in the company. Then, of course, we're all optimistic that we're gonna get a SiLO TFX approval, which would be, you know, the third product. The DEXA-C, the DEXA-L, and the SiLO TFX all to be used this year before the year is over. Then that would really cue us up nicely for next year because although DEXA-L and DEXA-C don't need surgical training, the doctors are very familiar. SiLO TFX would go right into our training protocols for ZIP, SiLO, and SiLO TFX. We would add that to our training protocols. My suspicions would be that we would have to probably increase our attendance, you know, our locations, because I think we would have a windfall of doctors that would really wanna be part of that SiLO TFX training protocol. Wonderful. Two more questions, and I'll leave it to others. So far, you've trained 200 doctors this year, and I believe you said you planned on training another 200. Was that correct for 2022? Between the trainings and the presenting to the ones, like some who don't necessarily go into a cadaver lab, they go into, say, a sawbone training or they have an in-office training. Yeah. We're gonna train more doctors, double it up from last year to this year, for sure. Okay. Do you foresee a $5 million quarter in the second half? You've done $4 million now, which is wonderful. Do you forecast or do you see, given the growth, the doctor training, the adoption, new products, DEXA-L or actually DEXA-C first, DEXA-L will just be an alpha at the stage at the end of the year. Do you forecast continued growth as we've seen and the possibility of a $5 million quarter? Yeah. Without any real guidance on this, I'm optimistic that we can get to that $5 million, you know, fourth quarter, right? I think in the fourth quarter that if everything lines up the way we want it to, especially with everything, the products that are rolling out, for us to achieve a $5 million quarter and then be able to, you know, continue to expand off that. You've heard me use words like springboard off each quarter, and we did that last year. Each quarter we went through, we springboarded off of one quarter to the next quarter in a positive direction, going upward that is. Reducing, you know, costs and then improving margin and able to really get closer and closer, and then indeed show some profitability into the fourth quarter and then going into next year is our goal. Yeah, I think it's there. It's right there. It's a matter of procedures. I'm not worried about the COVID. I'm not worried, not as worried about supply chain as I was in the first half of the year. It's now we have to execute, and we've got the products to do it. I know the team's really excited about selling the DEXA technology, and everyone's been holding their breath all year long for the TFX 'cause it really gives us a lot to talk about. We've got a training program in place for doctors to be ready to go on TFX. We've got early adopters and many people that will be excited about DEXA-C, one, because we're gonna be participating at the North American Spine Society, NASS, which will be in Chicago this year. Last year, NASS was in Boston. It was not well attended, and I think it had a lot to do with still the COVID and people traveling. I think that Chicago could be a better trade show. If it is, I always run into new customers at NASS, and this would, you know, we have a full booth available. We'll be able to do demonstrations in the booth to show the DEXA-C technology, and I think we'll be able to pick up doctors who wanna use DEXA-L in the future and now start to shift over to the DEXA-C. If in October, we have a TFX announcement, that'll be a great place to introduce the TFX at the North American Spine Society conference, followed up by our PSPS meeting, which is gonna be in Las Vegas here, also in October. We're gonna have a really busy trade show, fourth quarter. We have a cadaver course coming up here in Austin here in September, and we have several products to introduce to these doctors, throughout the rest of the year. Wonderful. Actually, I apologize, I do have one other question. It was actually geared towards Chad, and that was regarding the cash on the balance sheet of $750,000. You'd mentioned you have enough cash to see it through. There's no need to raise capital here. Can you elaborate on that? I see the receivables have grown over $4 million. Right. Have you been able to collect within a timely fashion? Is this just a function of the growth rate? Is increasing and, obviously- Right Maybe you can just elaborate. Sure. You know, June was a very big month for us. I think it came in at $1.5 million. Obviously, that puts our, you know, that'll increase our receivables in and of itself. Yeah, we've really started to focus, you know, once we hit the $4 million mark, we really kind of bear down and focus on the receivables. When I say I think we've got enough cash and, you know, obviously that involves collecting receivables. We haven't really had any much loss there in the past, and I don't see much in the future, so I believe it's almost all of its collectible. You know, if we collect it in a timely fashion like we've been trying to do and we've been succeeding the last month, I think we'll be fine with cash. I don't think we'll need to raise any. Okay. Perfect. Well, thank you guys for your time. I'll leave it to others to ask questions as they will. But thank you again, and congratulations on a wonderful quarter there, guys. Thank you, Tom. Thanks, Tom. Once again, if you would like to ask a question, please press star then one. This will conclude our Q&A session. I'd like to turn the conference back over to Trent Northcutt for any closing remarks. Thank you for joining us. We appreciate your time and interest in Aurora Spine. We are very excited about what's ahead of us in 2022 and beyond. We look forward to speaking to many of you in the weeks ahead. If you have any questions, please reach out to Adam at Lytham Partners, and we'd be happy to schedule a follow-up call. Thanks again. Everyone have a great rest of your day. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect your lines at this time.